

FOR UK MEDICAL AND TRADE MEDIA ONLY**Lupin Healthcare UK Ltd. announce the development of respiratory inhalers with near-zero global warming potential propellants, as part of their net zero plans**

- *Lupin's R&D teams are working on reformulating products in their pMDI portfolio with a near-zero global warming potential propellant*
- *The development is aligned with European and UK regulatory requirements*
- *This is a critical part of Lupin UK's sustainability efforts, which include specific commitments to achieve net-zero status by 2045*

Berkshire, United Kingdom, September 09, 2024: Lupin Healthcare (UK) Limited, the wholly owned subsidiary of Lupin Limited (Lupin), has unveiled its strategy to reformulate products in their pMDI portfolio by incorporating a propellant with near net-zero global warming potential. This initiative aims to provide patients with products that maintain the same efficacy and safety profile, while significantly reducing their environmental impact compared to existing options.

Ben Ellis, UK General Manager, Lupin Healthcare said, "If our product developed with the new propellant succeeds, we expect development work to complete in 2026 and regulatory filing to commence shortly after. This will be a key milestone for us on our carbon reduction journey, and ensure long-term options for patients and prescribers."

Vinita Gupta, Chief Executive Officer, Lupin said, "We are committed to making a positive impact in the lives of asthma patients worldwide. Our focus is on patient-centric sustainable healthcare innovation, ensuring that those who receive our pMDIs have reliable access to effective treatments with minimal impact to the environment."

Mona Bafadhel, Director of the King's Centre for Lung Health and Professor of Respiratory Medicine, King's College London said, "The ideal inhaler is the one that a patient can and will use. The advent of pMDIs with greener propellants will allow us to continue to prescribe these devices whilst having less impact on the environment."

The burden of chronic respiratory disease

It is estimated that there are at least 300 million patients living with asthma and 328 million patients living with COPD worldwide, making them the most common chronic respiratory diseases.¹ Inhalers are used to reduce morbidity and mortality associated with these diseases and significantly improve quality of life.¹

Current pMDI inhalers used for the management of COPD and asthma use a greenhouse gas to act as a propellant. While the propellant delivers the medicine to the lungs it also contributes to climate change.² It is estimated that pMDIs are responsible for approximately 3% of the NHS's carbon footprint in the UK.³

A study from Asthma + Lung UK identified that most patients would like the environmental impact of inhalers to be a consideration in treatment choice.⁴ By initiating work to reformulate their pMDI platform with near-zero global warming propellants, Lupin Healthcare (UK) believe they are supporting access and choice.

About Lupin

Lupin Healthcare is a subsidiary of the global pharmaceutical company, Lupin Limited who are a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit www.lupinhealthcare.co.uk

For further information or queries please contact –

Matt Duggan

Associate Director - Marketing, Lupin Healthcare UK

Email: matthewduggan@lupin.com

Tel: 07341378715

Hayley Kane

Director, Vivari Communications

Email: hayley@vivaricomunications.com

Tel: 07712 410850

References

1. Pernigotti D, Stonham C, Panigone S, Sandri F, Ferri R, Unal Y, Roche N. Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries. *BMJ Open Respir Res.* 2021 Dec;8(1):e001071.
2. Asthma + Lung UK; How inhalers affect the environment: <https://www.asthmaandlung.org.uk/conditions/asthma/how-inhalers-affect-environment#:~:text=These%20types%20of%20inhalers%20are,but%20contribute%20to%20climate%20change>. Accessed: September 2024
3. Usmani OS, Levy ML. Effective respiratory management of asthma and COPD and the environmental impacts of inhalers. *NPJ Prim Care Respir Med.* 2023 Jul 1;33(1):24.
4. NHS England; Improving health outcomes for respiratory patients while reducing carbon emissions: <https://www.england.nhs.uk/greenernhs/whats-already-happening/improving-health-outcomes-for-respiratory-patients-while-reducing-carbon-emissions/>. Accessed: September 2024